Intensive intravenous infusion of insulin in diabetic cats by Hafner, M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Intensive intravenous infusion of insulin in diabetic cats
Hafner, M; Dietiker-Moretti, S; Kaufmann, K; Mueller, C; Lutz, T A; Reusch, C E; Zini, E
Abstract: BACKGROUND Remission occurs in 10-50% of cats with diabetes mellitus (DM). It is as-
sumed that intensive treatment improves ￿-cell function and increases remission rates. HYPOTHESIS
Initial intravenous infusion of insulin that achieves tight glycemic control decreases subsequent insulin
requirements and increases remission rate in diabetic cats. ANIMALS Thirty cats with newly diagnosed
DM. METHODS Prospective study. Cats were randomly assigned to one of 2 groups. Cats in group 1 (n
= 15) received intravenous infusion of insulin with the goal of maintaining blood glucose concentrations
at 90-180 mg/dL, for 6 days. Cats in group 2 (n = 15) received subcutaneous injections of insulin glargine
(cats ￿4 kg: 0.5-1.0 IU, q12h; >4 kg 1.5-2.0 IU, q12h), for 6 days. Thereafter, all cats were treated with
subcutaneous injections of insulin glargine and followed up for 6 months. Cats were considered in remis-
sion when euglycemia occurred for ￿4 weeks without the administration of insulin. Nonparametric tests
were used for statistical analysis. RESULTS In groups 1 and 2, remission was achieved in 10/15 and in
7/14 cats (P = .46), and good metabolic control was achieved in 3/5 and in 1/7 cats (P = .22), respec-
tively. Overall, good metabolic control or remission occurred in 13/15 cats of group 1 and in 8/14 cats
of group 2. In group 1, the median insulin dosage given during the 6-month follow-up was significantly
lower than in group 2 (group 1: 0.32 IU/kg/day, group 2: 0.51 IU/kg/day; P = .013). CONCLUSIONS
AND CLINICAL IMPORTANCE Initial intravenous infusion of insulin for tight glycemic control in cats
with DM decreases insulin requirements during the subsequent 6 months.
DOI: 10.1111/jvim.12449
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-99983
Accepted Version
Originally published at:
Hafner, M; Dietiker-Moretti, S; Kaufmann, K; Mueller, C; Lutz, T A; Reusch, C E; Zini, E (2014). Inten-
sive intravenous infusion of insulin in diabetic cats. Journal of Veterinary Internal Medicine, 28(6):1753-
1759. DOI: 10.1111/jvim.12449
 1 
INTENSIVE INTRAVENOUS INFUSION OF INSULIN IN CATS WITH 1 
DIABETES MELLITUS 2 
 3 
M. Hafner, S. Dietiker-Moretti, K. Kaufmann, C. Mueller, T.A. Lutz, C.E. Reusch, E. Zini 4 
 5 
From the Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 6 
Winterthurerstrasse 260, 8057 Zurich, Switzerland (M. Hafner, S. Dietiker-Moretti, K. 7 
Kaufmann, C. Mueller, C.E. Reusch, E. Zini); Institute of Veterinary Physiology, Vetsuisse 8 
Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland (T.A. Lutz); 9 
Department of Animal Medicine, Production and Health, viale dell'Università 16, 35020 10 
Legnaro (PD), University of Padova, Italy (Zini); and Istituto Veterinario di Novara, Strada 11 
Provinciale 9, 28060 Granozzo con Monticello (NO), Italy (Zini). 12 
 13 
Corresponding author: Eric Zini 14 
Mailing address: Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of 15 
Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland. 16 
Phone: +41-44-6358112 17 
Fax: +41-44-6358930 18 
E-mail: ezini@vetclinics.uzh.ch 19 
 20 
Short title: intensive insulin therapy in cats. 21 
 22 
Abbreviations 23 
DM, diabetes mellitus; CGMS, continuous glucose monitoring system; PBGM, portable 24 
blood glucose meter. 25 
  2 
 26 
Keywords: Endocrinology, Pancreas, Feline, Hyperglycemia, Treatment. 27 
 28 
Acknowledgment 29 
Conflict of Interest: Authors disclose no conflict of interest. 30 
The study is partly supported by a grant from the Policlinico di Monza, Italy. 31 
 32 
 3 
Abstract 33 
Background―Remission occurs in 10-50% of cats with diabetes mellitus. It is assumed that 34 
intensive treatment improves β-cell function and increases remission rates. 35 
Hypothesis―Initial intravenous infusion of insulin that achieves tight glycemic control 36 
decreases subsequent insulin requirements and increases remission rate in diabetic cats. 37 
Animals―Thirty cats with newly diagnosed diabetes mellitus. 38 
Methods―Prospective study. Cats were randomly assigned to one of 2 groups. Cats in group 39 
1 (n=15) received intravenous infusion of insulin with the goal of maintaining blood glucose 40 
concentrations at 90-180 mg/dL, for 6 days. Cats in group 2 (n=15) received subcutaneous 41 
injections of insulin glargine (cats ≤ 4 kg: 0.5-1.0 IU, q12h; > 4 kg 1.5-2.0 IU, q12h), for 6 42 
days. Thereafter, all cats were treated with subcutaneous injections of insulin glargine and 43 
followed up for 6 months. Cats were considered in remission when euglycemia occurred for 44 
≥4 weeks without the administration of insulin. Nonparametric tests were used for statistical 45 
analysis. 46 
Results―In groups 1 and 2, remission was achieved in 10/15 and in 7/14 cats (p=0.46), and 47 
good metabolic control was achieved in 3/5 and in 1/7 cats (p=0.22), respectively. Overall, 48 
good metabolic control or remission occurred in 13/15 cats of group 1 and in 8/14 cats of 49 
group 2. In group 1, the median insulin dosage given during the 6-month follow-up was 50 
significantly lower than in group 2 (group 1: 0.32 IU/kg/day, group 2: 0.51 IU/kg/day; 51 
p=0.013). 52 
Conclusions and clinical Importance―Initial intravenous infusion of insulin for tight 53 
glycemic control in cats with diabetes mellitus decreases insulin requirements during the 54 
subsequent 6 months.55 
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Diabetes mellitus (DM) is a frequent endocrine disease in cats. Approximately 80% of 56 
diabetic cats are believed to have a form similar to type 2 diabetes in humans, which is 57 
characterized by inadequate insulin secretion and impaired insulin action.1 Current 58 
cornerstones of diabetes management in cats are twice daily injections of insulin and feeding 59 
a high-protein and low-carbohydrate diet. Ten to 50% of diabetic cats experience remission 60 
and no longer require exogenous insulin because of resolution of clinical signs and 61 
normalization of blood glucose and fructosamine concentrations.2-7 62 
A number of trials in human medicine evaluated short-term intensive administration of insulin 63 
in the management of newly diagnosed type 2 diabetic patients.8-12 Treatment included either 64 
multiple daily injections or continuous subcutaneous infusion of insulin for 2 to 3 weeks. 65 
Early intensive insulin therapy resulted in improvement of β–cell function and prolongation of 66 
remission.10 In addition, remission rates after 1 year were significantly higher in humans 67 
treated with intensive insulin therapy compared with those treated with oral hypoglycemic 68 
agents.10-12 The effect of intensive insulin therapy in cats needs to be explored; to date, only 69 
two studies have investigated this treatment modality using the long-acting insulin analogs 70 
glargine and detemir.13,14 Owners were required to follow a strict treatment protocol that 71 
included measurement of blood glucose several times per day. In both studies, remission rates 72 
of up to 64% and 67% were achieved, which might suggest that intensive insulin treatment is 73 
beneficial in cats.13,14 74 
Because intensive insulin treatment is associated with favorable results in human patients with 75 
type 2 diabetes and appears to be advantageous in diabetic cats, the aim of this investigation 76 
was to determine the effect of early and tight glycemic control using short-term intravenous 77 
infusion of insulin in cats with newly diagnosed diabetes. 78 
 5 
Materials and Methods 79 
 80 
Animals 81 
Cats with newly diagnosed diabetes were enrolled in the study from July 2008 to January 82 
2011. Cats were excluded from the study if they had received insulin therapy for longer than 1 83 
week before admission and if glucocorticoids or progestagens had been administered during 84 
the previous 4 months. All cats underwent a thorough evaluation including physical 85 
examination, complete blood cell count, serum biochemical profile, measurement of 86 
fructosamine and total T4 concentrations, urinalysis, including bacterial culture and urinary 87 
protein-to-creatinine ratio, blood pressure measurement, abdominal and thoracic radiographs 88 
and abdominal ultrasonography. Diabetic cats with ketoacidosis were included in the study if 89 
acidemia resolved and their general condition improved within 48 hours of insulin therapy. 90 
Cats with concurrent diseases at diagnosis (e.g., renal failure, gastrointestinal disorders, heart 91 
disease, other endocrinopathies, neoplasia) were not enrolled. 92 
The study was approved by the Cantonal Veterinary Office of Zurich and conducted in 93 
accordance with guidelines established by the Animal Welfare Act of Switzerland 94 
(permission no.: 83/2008). Informed consent to participate in the study was provided by the 95 
owners. 96 
 97 
Randomization and treatments 98 
Enrolled cases were hospitalized for 7 consecutive days. The cats were allocated to one of two 99 
treatment groups using a softwarea providing a partial minimization procedure to adjust the 100 
randomization probabilities between groups and to balance for covariates collected at 101 
baseline. The covariates sex, age, body weight, treatment with insulin before admission (i.e., 102 
for <1 week), presence of ketoacidosis, blood glucose and serum fructosamine concentrations 103 
were selected. 104 
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After the initial work-up, all cats were sedated with midazolam/butorphanolb,c and 105 
anesthetized with propofold to place a central venous cathetere in the jugular vein and to insert 106 
the sensor of the continuous glucose monitoring system (CGMS)f in the subcutaneous tissue 107 
of the lateral chest wall, as described previously.15-17 The CGMS measures glucose in the 108 
subcutaneous interstitial fluid every 10 seconds and displays the 5-minute average on the 109 
monitor. After a 2-hour period of initialization, the first calibration was carried out; thereafter 110 
the CGMS was calibrated after 6 hours and then every 10 hours. To calibrate the CGMS, 111 
capillary blood glucose was measured with a portable blood glucose meter (PBGM)g, 112 
validated for the cat.18 In addition to CGMS measurements, capillary blood glucose 113 
concentrations were also determined with the PBGMg every 4 to 6 hours to ensure reliability 114 
of the system. 115 
Cats of group 1 received intravenous infusion of insulin for 6 consecutive days with the goal 116 
of achieving tight glycemic control by adjusting the insulin dosage as required. Insulin was 117 
infused via the central venous catheter. The insulin solution consisted of 12.5 IU rapid-acting 118 
insulin asparth dissolved in 250 ml 0.9% NaCl. The solution was renewed daily, and the tube 119 
was flushed with the same solution to prevent insulin adsorption to the solid surfaces of the 120 
infusion sets.19 The initial insulin dosage used in the infusion was 0.05 IU/kg/h (equal to 1 121 
mL/kg/h). In addition, 0.9% NaCl infusion was given concurrently through the same catheter, 122 
and the infusion rate was adjusted to maintain the total amount of intravenous fluids at 2 123 
ml/kg/h. The cats were monitored 24 hours a day. The infusion rate of insulin was adjusted to 124 
achieve a target glucose concentration range of 90 to 180 mg/dL. For this purpose, the 125 
infusion rate of insulin was adjusted in steps of 0.025-0.05 IU/kg/h, every 15-30 minutes, if 126 
necessary. The infusion of insulin was discontinued at 6:00 am on day 7 of hospitalization, 127 
and at 8:00 am, the cats were started on subcutaneous injections of insulin glarginei. To 128 
ensure that the same dosage conversion was used for each cat, an arbitrary calculation was 129 
used. The total amount of insulin infused intravenously on day 6 was divided by 4. This 130 
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calculated dosage was administered twice daily on day 7, while the cats were still being 131 
monitored by the CGMS. The cats were discharged on day 8 with insulin injections 132 
prescribed twice daily. If glucose concentrations dropped below 72 mg/dL on day 7 or 8, the 133 
insulin dosage was reduced by 50%. 134 
Cats of group 2 were treated during the same 7-day period of hospitalization as cats of group 135 
1 and received subcutaneous injections of insulin glargine;i tight glycemic control was not a 136 
goal in this group. The insulin dosage was 0.5-1.0 IU, q12h, in cats weighing <4 kg and 1.5-137 
2.0 IU, q12h, in cats >4 kg. Additionally, all cats received an infusion of 0.9% NaCl via the 138 
central venous catheter at a rate of 2 ml/kg/h. The subcutaneous dosage of insulin was not 139 
adjusted during the 7-day period unless the blood glucose concentration dropped below 72 140 
mg/dL, in which case the insulin dosage was reduced by 50%. The insulin dosage was 141 
increased by 0.5 IU per cat, q12h, if hyperglycemia persisted after the 7 days of 142 
hospitalization. 143 
All cats of both groups were fed a high-protein, low-carbohydrate dietj during hospitalization 144 
and after discharge from the clinic. The study was carried out by two internal medicine 145 
residents under the supervision of two board-certified specialists in internal medicine. Cats 146 
were continuously monitored during the 7 days. 147 
 148 
Analyses during hospitalization 149 
To calculate the duration of time that glucose was within and outside the target range in cats 150 
of group 1, the glucose concentrations recorded by the CGMS and calibrated with the PBGM 151 
were divided into the following ranges: hypoglycemia (<90 mg/dL), target range (90-180 152 
mg/dL) and hyperglycemia (mild: 181-270 mg/dL; and moderate to severe: >270 mg/dL). 153 
This calculation included all glucose values recorded with the CGMS starting 12 hours after 154 
initiation of the insulin infusion (group 1) or after the first insulin injection (group 2), until 155 
day 7 at 6:00 am. The percentage of glucose measurements within each glycemic range was 156 
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calculated for each cat in both groups. On day 8, a blood sample was collected for 157 
determination of a complete blood cell count, serum biochemical profile and fructosamine 158 
concentration in all cats. The central venous catheter was then removed, and bacterial culture 159 
of the catheter tip was carried out. 160 
Serum potassium and phosphorus concentrations were measured at admission and discharge 161 
in all cats, At admission, if hypokalemia or hypophosphatemia was documented, 162 
supplementation was provided with potassium chloride or phosphate diluted in the 0.9% NaCl 163 
infusion and electrolytes were measured every 2 to 6 hours until the concentration 164 
normalized. During hospitalization, serum potassium and phosphorus concentrations were 165 
measured only if clinical signs compatible with electrolyte abnormalities were documented. 166 
 167 
Follow-up 168 
Re-evaluations were scheduled 1, 2-3, 6-8, 12-16 and 24 weeks after discharge from the clinic 169 
and were carried out by the same internal medicine residents who cared for the cats during the 170 
first week of hospitalization. The insulin dosage was adjusted based on clinical signs and the 171 
results of physical examination, blood glucose curves and fructosamine levels;1 the goal was 172 
to resolve clinical signs of DM and to maintain blood glucose curves between 90 and 270 173 
mg/dL and fructosamine concentrations <400 µmol/L. To exclude the development of 174 
concurrent diseases, diagnostic tests including a complete blood cell count, serum 175 
biochemical profile, fructosamine concentration, urinalysis, urinary protein-to-creatinine ratio 176 
and blood pressure measurement were done at each re-evaluation. Abdominal 177 
ultrasonography and total T4 measurement were carried out 6-8 weeks and 24 weeks after 178 
hospitalization. A dexamethasone suppression test was done 6-8 weeks after discharge from 179 
the clinic to rule out hyperadrenocorticism. Remission of diabetes was defined as absence of 180 
signs of DM (e.g., polyuria/polydipsia, polyphagia) with normal blood glucose (72-162 181 
mg/dl) and fructosamine concentrations (<340 µmol/L) for at least 4 weeks after 182 
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discontinuation of the insulin injections.1,4,5 In cats in which remission occurred before insulin 183 
administration had been discontinued, the dosage was decreased in increments of 0.5 IU per 184 
dosage, once weekly. The last dosage before insulin was discontinued was 0.5 UI once daily, 185 
for at least one week. The onset and duration of remission were recorded. Good metabolic 186 
control was defined as absence of clinical signs of DM, fructosamine concentrations <400 187 
µmol/L and blood glucose curve measurements ranging from 90 to 270 mg/dL.1 In both 188 
groups, the median insulin dosage per kg per day was calculated over the 6-month study 189 
period; phases of remission were excluded from the calculation. 190 
 191 
Statistical analysis 192 
Data are presented as median and ranges. Differences in rate of remission and rate of good 193 
metabolic control between groups were analyzed using Fisher’s exact test. Differences in 194 
laboratory results, blood pressure measurements, glucose measurements within each glycemic 195 
range during hospitalization, onset of remission and daily insulin dosage given over the 6-196 
month study period between groups were analyzed using the Mann-Whitney U test. A 197 
commercial softwarek was used for all analyses. The level of significance was set at p<0.05. 198 
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Results 199 
Animals 200 
A total of 51 cats with newly diagnosed DM were admitted to our clinic during the study 201 
period. Thirty cats fulfilled the inclusion criteria and were enrolled in the study; each of the 2 202 
groups consisted of 15 cats. In group 1, the median age was 11.0 years (range: 7.0-15.0) and 203 
median body weight was 5.8 kg (range: 3.4-9.0). Eleven were domestic shorthair or longhair 204 
cats, and 4 were purebred cats (Abyssinian, Burmese, Siamese and Norwegian forest cat). 205 
Nine cats were neutered males and six were spayed females. In group 2, the median age was 206 
11.0 years (range: 8.0-17.0) and median body weight was 4.7 kg (range: 2.5-9.6). Fourteen 207 
were domestic shorthair or longhair cats and one was a Ragdoll cat. Eight cats were neutered 208 
males and seven were spayed females. There was no significant difference in gender, age or 209 
bodyweight between the two groups. At the time of initial presentation, 2 of the cats enrolled 210 
in the study had ketoacidosis, which resolved within one day of intramuscular injections of 211 
insulin; one was allocated to group 1 and the other to group 2. In group 2, 1 cat died of 212 
pyelonephritis (3 months after admission) and another died of alimentary lymphoma (3 days 213 
before the end of the study). Only cats that were alive for the duration of the study were 214 
included in the analysis; the cat that died 3 months after admission was excluded. 215 
 216 
Laboratory results and blood pressure measurement on admission 217 
In group 1, the median serum glucose concentration was 439 mg/dL (range: 203-581) and the 218 
median fructosamine concentration was 615 µmol/L (range: 528-783). In group 2, the median 219 
serum glucose concentration was 425 mg/dL (range: 248-560) and the median fructosamine 220 
concentration was 575 µmol/L (range: 449-778). The laboratory results and blood pressure 221 
measurements at the time of admission are shown in Table 1. There were no significant 222 
differences between groups. 223 
 224 
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Intensive intravenous infusion of insulin 225 
In group 1, blood glucose concentrations decreased to the target range within 12 hours of 226 
initiation of treatment in 13 of 15 cats. In those cats, it was necessary to reduce the insulin 227 
infusion rate to 0.02-0.03 IU/kg/h to avoid hypoglycemia. In 2 obese cats with a body 228 
condition scorel of 9 out of 9, the initial insulin infusion rate was not sufficient to achieve the 229 
target glucose concentration within 12 hours and it was therefore increased to 0.07 IU/kg/h. 230 
Within 24 hours, all 15 cats had blood glucose concentrations within the target range. In 2/15 231 
cats of group 1, the glucose concentration decreased below 72 mg/dL during the 6-day 232 
infusion, and the insulin infusion was stopped temporarily. On day 7, 2 of the cats received 233 
0.5 IU, 8 received 1 IU, 4 received 2 IU and 1 received 3 IU of insulin injected 234 
subcutaneously, q12h. Bacterial culture of the tip of the jugular catheter after removal 235 
revealed bacterial growth in 2 cats; one culture yielded Pseudomonas aeruginosa and the 236 
other Enterococcus spp.. 237 
 238 
Subcutaneous injections of insulin 239 
In group 2, nine of the 15 cats weighed <4 kg; the initial dosage of insulin injected 240 
subcutaneously was 0.5 IU, q12h, in 1 cat and 1.0 IU, q12h, in the other 8. Of the 6 cats that 241 
weighed >4 kg, 4 received an initial dosage of insulin injected subcutaneously of 1.5 IU, 242 
q12h, and 2 received 2.0 IU, q12h. In 4 of the 15 cats of group 2, glucose concentrations 243 
decreased to the target range within 12 hours. During hospitalization, 4 of the 15 cats of group 244 
2 had glucose concentrations <72 mg/dL, which necessitated a 50% decrease in the insulin 245 
dosage for the remainder of the study; the dosage was reduced after a median of 2.6 days 246 
(range: 0-4). One of those 4 cats had normoglycemia at the time of discharge (day 8), and 247 
insulin was therefore not prescribed. In 6 of the 15 cats the insulin dosage was increased at the 248 
time of discharge because the amount given during hospitalization was considered insufficient 249 
for adequate glycemic control; the insulin dosage was increased to 1 IU in one cat, to 1.5 IU 250 
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in two cats and to 2 IU in the remaining three cats, administered subcutaneously, q12h. 251 
Bacterial culture of the tip of the jugular catheter after removal revealed bacterial growth of 252 
Pantoea agglomerans in one cat and Acinetobacter spp. in one other. 253 
 254 
Analyses during hospitalization and costs 255 
To determine whether short-term intravenous infusion of insulin maintained blood glucose 256 
levels within the target range during hospitalization, the percentage of glucose measurements 257 
that fell into different concentration ranges was compared with those of cats that were started 258 
on subcutaneous injections of insulin without aiming at tight glycemic control. The 259 
percentage of glucose measurements for cats within the target range of 90-180 mg/dL was 260 
significantly higher for cats in group 1 than in group 2 [group 1: median 59% (range: 15-96); 261 
group 2: median 16% (range: 0-65); p=0.001]. The percentage of glucose measurements with 262 
moderate to severe hyperglycemia (>270 mg/dL) was significantly lower for cats in group 1 263 
than in group 2 [group 1: median 5% (range: 0-40); group 2: median 42% (range: 0-100); 264 
p=0.004)]. The percentage of glucose measurements for each cat within the range of mild 265 
hyperglycemia (181-270 mg/dL) [group 1: median 27% (range: 0-45); group 2: median 20% 266 
(range: 0-83)] and of hypoglycemia (<90 mg/dL) [group 1: median 0% (range: 0-30); group 2: 267 
median 0% (range: 0-40)] did not differ significantly between groups. 268 
In both groups, median fructosamine concentrations decreased significantly after one week of 269 
hospitalization [admission vs. discharge: group 1, 615 µmol/L (range: 528-783) vs. 402 270 
µmol/L (range: 322-528), p<0.0001; group 2, 575 µmol/L (range: 449-778) vs. 441 µmol/L 271 
(range: 351-527), p<0.001]. Fructosamine concentrations at discharge did not differ 272 
significantly between groups. 273 
On admission 3 cats presented with mild hypokalemia (range: 3.3-3.7 mEq/L; reference 274 
range: 3.8-5.4) and 5 with mild hyperkalemia (range: 5.5-6.5 mEq/L), 2 cats presented with 275 
mild hypophosphatemia (1.8 and 2.0 mg/dL, respectively; reference range: 2.8-5.6) and one 276 
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with mild hyperphosphatemia (6.2 mg/dL). Abnormal serum potassium or phosphorus 277 
concentrations normalized within 24 hours from admission; potassium chloride or phosphate 278 
supplementation was provided in cats with hypokalemia or hypophosphatemia, respectively. 279 
None developed clinical signs suggestive of electrolyte imbalance during the period of 280 
hospitalization. At discharge all cats had normal serum potassium concentrations and all but 281 
one had normal phosphorus. The cat with abnormal serum phosphorus had very mild 282 
hyperphosphatemia (5.8 mg/dL). There were no differences between groups at admission and 283 
discharge for either electrolyte. 284 
The cost of the 6-day intensive intravenous infusion of insulin was approximately US$1,700 285 
per cat. 286 
 287 
Diabetic remission and metabolic control during follow-up 288 
The remission occurred in 10/15 in group 1 and in 7/14 in group 2, p=0.462. Of the cats that 289 
went into remission, relapse occurred 4 weeks after insulin had been discontinued in one cat 290 
of group 1 and 7 weeks after discontinuation of insulin in one cat of group 2. The remaining 291 
cats were in remission until the end of the study. In the majority of all cats, remission 292 
occurred within 16 weeks of discharge (Table 2). The onset of remission did not differ 293 
between groups. 294 
Good metabolic control was obtained in 3/5 cats that did not achieve remission in group 1, 295 
and in 1/7 cats that did not achieve remission in group 2 (p=0.222). Overall, good metabolic 296 
control or remission was achieved in 13/15 cats in group 1 and in 8/14 cats in group 2. During 297 
the 6-month follow-up period, the median insulin dosage was significantly lower in group 1 298 
cats compared with group 2 [group 1: 0.32 IU/kg/day (range: 0.13-0.53); group 2: 0.51 299 
IU/kg/day (range: 0.05-1.52); p=0.013] (Figure 1). 300 
During the 6-month follow-up period, 9 cats developed concurrent diseases, including chronic 301 
kidney disease (n=4, 3 in group 1, 1 in group 2), hyperthyroidism (n=2, 1 in each group), 302 
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acute pancreatitis and hyperadrenocorticism (1 in group 2), pyelonephritis (1 in group 2) and 303 
alimentary lymphoma (1 in group 2). 304 
 1
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Discussion 305 
Intravenous infusion of insulin was effective in quickly reducing glucose concentrations to 306 
within the target range, and compared with subcutaneous injections of insulin, prevented long 307 
periods of moderate to severe hyperglycemia (i.e., >270 mg/dL). Glucose concentrations were 308 
rarely below the reference range, and episodes of clinical hypoglycemia did not occur. These 309 
findings support the conclusion that our method of intensive intravenous infusion of insulin 310 
can be safely used to rapidly decrease hyperglycemia without adverse effects. In previous 311 
studies, we demonstrated that CGMS is clinically accurate for generating 12- and 24-hour 312 
glucose curves in diabetic cats.15,16 The results of the present study showed that a CGMS is a 313 
valuable tool for long-term monitoring of glucose curves (i.e., one week) in hospitalized cats 314 
and allows fine-tuning of the insulin dosage. 315 
Remission occurred in 10/15 cats initially treated with intensive intravenous infusion of 316 
insulin compared to 7/14 cats treated with subcutaneous injections of insulin. When cats that 317 
went into remission were excluded, good glycemic control was achieved in 3/5 cats that had 318 
been initially treated with intensive intravenous infusion of insulin and in 1/7 cats treated with 319 
subcutaneous injections of insulin. However, differences between the 2 groups were not 320 
significant, possibly because of the relatively low number of cats in the study. It was 321 
interesting to note that cats started on intensive intravenous infusion of insulin required 322 
significantly less insulin than cats started with subcutaneous injections of insulin 323 
(approximately 40% less, based on differences between median values). Roomp and Rand 324 
carried out two intensive glucose monitoring studies in cats, one with insulin glargine and the 325 
other with insulin detemir.13,14 In both investigations, the aim was to achieve tight glycemic 326 
control by frequent monitoring of blood glucose concentration and adjustment of insulin 327 
dosage. Owners were asked to measure blood glucose concentrations of their diabetic cats at 328 
least three times daily at home and to adjust the insulin dosage with the help of a web-based 329 
protocol. The rate of remission was 64% in diabetic cats treated with insulin glargine and 67% 330 
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in diabetic cats treated with insulin detemir.13,14 Their rates of remission were similar to our 331 
results in cats started on intensive intravenous infusion of insulin. These results suggest that 332 
strict blood glucose monitoring and frequent insulin dosage adjustments are as effective as 333 
intensive intravenous infusion of insulin. However, the study design of those previous 334 
investigations differed substantially from that of the present study making direct comparison 335 
difficult. In the study by Roomp and Rand, owners of cats with DM were responsible for 336 
maintaining tight glycemic control,13 whereas in our study, veterinarians were in charge of 337 
insulin dosage adjustments. One would expect that treatment decisions made by veterinarians 338 
in a hospital setting are more consistent than those made by owners at home. In addition, it 339 
should be noted that in contrast to our study, a substantial percentage of the cats included in 340 
the study by Roomp and Rand had been treated with glucocorticoids before being diagnosed 341 
with DM.13 In our study, cats with prior steroid therapy were excluded. The chance of 342 
remission in cats with glucocorticoid-induced DM is good,13 which may explain the slightly 343 
higher remission rate found in the glargine-treated cats in their study compared with the cats 344 
of group 2, in which initial tight glycemic control was not a goal. Of note, by excluding 345 
glucocorticoid-treated cats from that study,13 the remission rate would have decreased from 346 
64% to 51%, yielding a remission rate similar to our group 2 cats as well as to other cats 347 
started on subcutaneous injections of insulin without initial tight glycemic control.5 348 
Clinical studies in human medicine demonstrated that initial intensive infusion of insulin has 349 
positive effects on metabolic control in patients with newly diagnosed type 2 diabetes 350 
compared with oral antidiabetic drug therapy.10-12 This beneficial effect was attributable to 351 
improved β–cell function, evidence of which was seen as augmented glucose stimulated first-352 
phase insulin secretion after intensive infusion of insulin.12 The mechanisms involved in 353 
improved β–cell function after intensive insulin therapy in humans include reversal of 354 
glucotoxicity and lipotoxicity and/or reduction of islet inflammation, all of which contribute 355 
to loss of β–cell function and mass.20-22 Glucotoxicity is considered to be the major cause of 356 
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loss of β–cell function and mass.22 Similar to findings in humans, hyperglycemia has been 357 
shown to induce early and severe dysfunction and loss of β–cells via apoptosis in healthy 358 
cats.23-24 Thus, eliminating the detrimental effects of hyperglycemia using initial intensive 359 
infusion of insulin may improve β–cell viability in diabetic cats, ultimately decreasing insulin 360 
requirements for the maintenance of glycemic control. Evidence of this in the present study 361 
was the lower median insulin dosages required by cats in group 1. 362 
This study had some limitations including the relatively low number of cats; studying a larger 363 
number of cats may or may not have shown significant differences for rates of remission or 364 
good metabolic control. The follow-up period was set at 6 months and it is possible that this 365 
period was too short for remission to occur in some of the cats. However, based on an earlier 366 
study from our clinic, more than 90% of cats with newly diagnosed diabetes achieved 367 
remission within 6 months,5 and therefore the length of the follow-up period presumably had 368 
little effect on the remission rate. The central venous catheters from 4 cats yielded positive 369 
bacteriological cultures, but because none of these cats had related clinical or laboratory 370 
abnormalities, it was assumed that the adverse effect of the recovered microorganisms was 371 
negligible. Finally, fine-tuning of the insulin dosage to maintain blood glucose levels within 372 
the target range was difficult in some cats; concentrations above the target range occurred 373 
despite strict 24-hour monitoring. It is possible that in some cats this interfered with the 374 
beneficial effects of intensive intravenous infusion on β–cells. 375 
In summary, cats that initially received intensive intravenous infusion of insulin with tight 376 
glycemic control had significantly decreased insulin requirements in the 6-month-follow-up 377 
period. Remission rate and metabolic control did not differ significantly between the two 378 
groups, possibly because of the small number of cases. Intensive intravenous infusion of 379 
insulin is a demanding treatment, and owner compliance may not be satisfactory because of 380 
the high cost and the relatively long hospitalization period. 381 
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Footnotes 382 
aMinim (Altman DG, Bland JM), www.sghms.ac.uk/depts/phs/guide/randser.htm. 383 
bDormicum, Roche Pharma, Reinach, Switzerland. 384 
cMorphasol, Dr. E. Gräub, Bern, Switzerland. 385 
dPropofol 1% MCT, Fresenius Kabi, Stans, Switzerland. 386 
eCertofix Mono Paed S, B. Braun, Melsungen, Switzerland. 387 
fGuardian REAL-Time continuous glucose monitoring system, Medtronic, Munchenbuchsee, 388 
Switzerland. 389 
gAlphaTRAK portable blood glucose meter, Abbott Animal Health, Maidenhead, UK. 390 
hNovoRapid, Novo Nordisk Pharma, Kusnacht, Switzerland. 391 
iLantus, Sanofi Aventis, Meyrin, Switzerland. 392 
jDM Purina Veterinary Diets, Medical solution, Steinhausen, Switzerland. 393 
kGraphPad Prism version 4.0, GraphPad Software, La Jolla, CA, USA. 394 
lBody condition chart for the cat, Nestlé Purina PetCare Research, St. Louis, MO, USA. 395 
 396 
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Tables 456 
Table 1. Laboratory results and blood pressure measurements in cats on initial intensive 457 
intravenous infusion of insulin with tight glycemic control achieved by insulin dosage 458 
adjustment (group 1) and in cats started on subcutaneous injections of insulin without the goal 459 
of initial tight glycemic control (group 2). 460 
 461 
  Group 1 Group 2  
Parameter Unit Median Range Median Range 
Reference 
range 
Hematocrit % 39 31-49 38 23-42 33-45 
Leukocytes 103/µL 13.3 5.8-27.0 8.7 5.0-24.0 4.6-12.8 
Platelets 103/µL 306 192-594 322 194-649 180-680 
Glucose mg/dL 439.6 203.6-582.0 425.2 248.6-560.4 72-162 
Fructosamine µmol/L 615 528-783 575 449-778 202-340 
Cholesterol mg/dL 220.1 158.3-359.1 251.0 169.9-393.8 101-263 
Triglyceride mg/dL 141.6 35.4-557.5 119.5 44.2-2247.8 26.5-115.0 
Total proteins g/dL 7.7 7.0-9.1 7.4 5.8-8.5 6.4-8.0 
Albumin g/dL 3.4 2.9-4.1 3.5 2.6-3.9 3.0-4.0 
Urea mg/dL 27.7 16.0-35.3 10.3 12.3-15.6 20.7-35.3 
Creatinine mg/dL 1.2 0.8-2.0 1.1 0.7-1.6 1.1-1.8 
Sodium mEq/L 159 151-163 160 155-166 158-165 
Chloride mEq/L 113 103-121 115 109-119 121-131 
Potassium mEq/L 4.9 3.3-5.7 4.7 3.7-6.5 3.8-5.4 
Phosphorus mg/dL 3.8 1.8-6.2 3.7 2.0-5.6 2.8-5.6 
Calcium mg/dL 10.5 9.2-12.4 9.9 7.9-11.2 9.6-11.2 
 2
3 
Bilirubin mg/dL 0.08 0.02-0.22 0.08 0.02-0.16 0.1-0.4 
Lipase U/L 24 14-75 26 15-75 8-26 
ALP U/L 65 37-92 61 14-111 16-43 
ASAT U/L 34 21-91 36 15-137 19-44 
ALAT U/L 92 45-326 61 32-235 34-98 
Urine ketone 
bodies 
mg/dL 0 0-40 0 0-15 0 
UPC  0.41 0.02-1.64 0.24 0.03-2.82 ≤0.40 
Basal thyroxin µg/dL 1.5 0.5-2.5 1.0 0.5-2.5 <3.5 
Systolic blood 
pressure 
mm Hg 129 90-162 133 110-175 <160 
ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ASAT, aspartate 462 
aminotransferase; UPC, urine protein-to-creatinine ratio. 463 
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Table 2. Onset of remission in cats started on initial intensive intravenous infusion of insulin 464 
with tight glycemic control achieved by insulin dosage adjustment (group 1) and in cats 465 
started on subcutaneous injections of insulin without the goal of initial tight glycemic control 466 
(group 2). 467 
Onset of remission 
Group 1 
(number of cats) 
Group 2 
(number of cats) 
At discharge 0 1 
≤ 4 weeks after discharge 2 3 
5-6 weeks after discharge 2 0 
7-16 weeks after discharge 5 2 
> 16 weeks after discharge 1 1 
 2
5 
Figure captions 468 
Figure 1. Dot plots of median insulin dosage administered per kg body weight per day for 469 
each cat during the 6-month study period in cats on initial intensive intravenous infusion of 470 
insulin with tight glycemic control achieved by insulin dosage adjustment (group 1) and in 471 
cats started on subcutaneous injections of insulin without the goal of initial tight glycemic 472 
control (group 2). The horizontal lines mark the medians for each group. 473 
 474 
